Consumer Product of the Year Winner Announces Global Extra-Strength Option for Microdosing

In mid-October 2022, Gwella, a direct-to-consumer functional mushroom brand, is excited to announce the launch of its newest mushroom gummy. Mojo Microdose Gummies – Mojo Macro is an extra-strength version of the brand’s already popular regular-strength Mojo gummies. Gwella’s Mojo gummies offer a legal option for people to experience the benefits of microdosing: focus, energy, mental clarity, and feelings of positivity.

Growing Popularity

Touted as the world’s first legal microdose alternative, Gwella’s non-hallucinogenic gummies, Mojo Microdose gummies, quickly sold out during their 2021 release. In addition to receiving some excellent consumer reviews, Mojo also won Consumer Product of the Year during the 1st Annual Microdose Awards.

After a successful initial run, Gwella ramped up the production of its flagship product to meet a growing consumer base. In response to widespread international interest, the regular- and extra-strength Mojo gummies can now be shipped to customers worldwide, including the UK where consumer demand has been extremely high. Aside from a few countries with stricter restrictions on functional mushrooms, Mojo products are 100% legal.

Functional Ingredients

Mojo gummies are engineered with a stack of unique bioactives to stimulate the reported pharmacological benefits of microdosing psilocybin, without any of the legal worries.

Mojo uses proprietary Cordyceps that helps naturally boost mood, while the nootropics combined with Lion’s Mane help enhance focus and improve mental clarity. After taking Mojo gummies regularly, some users can decrease their daily caffeine intake without affecting their energy levels. The addition of ginseng and slow-releasing caffeine provide a non-jittery brain boost and a reduction in brain fog.

Microdosing magic mushrooms allow people to feel creative, clear-headed, and present. Gwella’s Mojo gummies help people explore the psychedelic world without the illegal components. According to Daniel Sanders, Gwella’s Chief Science Officer, Mojo’s “non-hallucinogenic, non-psychedelic formula leverages the adaptogenic and functional benefits of mushrooms to improve individual baselines across their health and productivity.”

The synergy of the active ingredients working together make the Mojo formula both safe and effective.

Short and Long-Term Benefits

As health and wellness continue to trend in a post-pandemic world, Mojo gummies serve as a legal microdose alternative that affords immediate and long-term wellness advantages. Gwella recommends taking no more than six gummies in a 12-hour period and alternating five days on and two days off if you plan on starting a routine.

In as little as a half-hour, users can experience a clean and consistent energy boost that mimics the flow state associated with microdosing for 5+ hours! For some, taking one Mojo gummy can increase focus, mental clarity, and calmness after the release period. Others may need to take more than one to experience their next level focus.

Long-term benefits, like improved mood and brain cognition, can occur when you take the gummies as part of a routine. Although Gwella doesn’t make medical claims since they haven’t conducted clinical trials yet, consumers have reported that taking Mojo gummies helps them get a midday pick-me-up, achieve better sleep and generally attain an improved mental state.

Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

Trondheim in central Norway will be the location of Awakn's 4th clinic

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the signing of a 5-year lease to open Awakn Clinics Trondheim. The new clinic is part of the second stage of Awakn's Nordic expansion plans, following on from last week's announcement of a move to a larger premises for its Oslo clinic.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
magic mushrooms

How Do Psychedelics Clinical Trials Work?

A flurry of clinical trials are at play in the psychedelics space as the industry waits for a landmark first approval.

Several publicly traded companies are pursuing the tried-and-true pharmaceutical path when it comes to drug development, drawing on lengthy and significant research in the hopes of eventually bringing their products to market.

To learn more about what steps psychedelics companies have to complete, the Investing News Network (INN) caught up with Dr. Amy Reichelt, director of neuropharmacology at Cybin (NYSEAMERICAN:CYBN,NEO:CYBN), following the recent Wonderland business conference. She outlined the drug development process with a focus on clinical trials.

Keep reading...Show less
Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its proprietary Psilocin based compound L-130.

Philip J. Young, Chairman and Chief Executive Officer of the Company stated, "Subsequent to our last communication on the cGMP production of L-130, I wanted to update our stakeholders on our progress as we advance into our Phase 1 clinical trials. We have received regulatory clearance to conduct our Phase 1 study which is a combination of safety and pharmacokinetics evaluation of a fixed dose of L-130." Young continued, "It is important to remember that we are approaching the development of a global commercial markets with a disruptive approach to treating anxiety conditions with sequential sub psychedelic dosing of our compounds. Since the majority of patients with anxiety related conditions are cared for by their personal family physician our goal is to create a treatment regimen that is effective and easily a prescribed by patient's personal physician."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
pink mushrooms under ultraviolet light

What Does the FDA Think About Psychedelics? (Updated 2022)

The development of the growing psychedelics industry depends on myriad factors, but one of the most critical is its relationship with a principal medical authority.

The US Food and Drug Administration (FDA) is the leading body for drug approvals in the US. Its job is to review clinical data from established medical studies on the feasibility of drug compounds or products as treatments for specific ailments.

Essentially, this federal body determines whether medical products will ultimately reach the hands of patients.

Keep reading...Show less

COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Evercore ISI HealthCONx Conference at 9:15am ET on 30 November 2022.

A live audio webcast of the fireside chat will be accessible from the "Events" page of the Investors section of the COMPASS website. The replay of the webcast will be accessible for 30 days following the event. For more information, please visit .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Albert Labs

Albert Labs Announces Private Placement

Albert Labs International Corp. (Albert Labs [CSE: ABRT] [FSE: VB50], the "Company"), a biopharmaceutical drug discovery company focused on gaining regulatory approval for active compounds to treat various mental health conditions, has announced a non-brokered private placement for gross proceeds of up to $3,000,000 (the "Offering"), with the first tranche raised at a price of CAD $0.08 per Unit (the "Units"); intermediate closings may take place as determined by the Company.

Each Unit is comprised of one common share (the "Common Share") and one-half of one whole Common Share purchase warrant (each whole warrant, a "Warrant") with each whole Warrant entitling the holder to purchase one additional Common Share of the Company at a price of CAD $0.12 per Share for a period of 12 months from the date of issuance. In the event that the Company's common shares have a closing price on the CSE of greater than CAD $0.15 per common share for a period of 10 consecutive trading days, the Company may accelerate the expiry date of the Warrants by giving notice to the holders thereof and, in such case, the Warrants will expire on the 30th day after the date on which such notice is given to the holder by the Company.

Keep reading...Show less

Latest Press Releases

Related News